Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
Ph.D Jennifer Hammond, M.D Carla Yunis, Pharm.D Robert J Fountaine, M.S Gerald Luscan, M.S Aimee M Burr, Ph.D Wuyan Zhang, Wayne Wisemandle, Ph.D Holly Soares, Mary Lynn Baniecki, Ph.D Victoria M Hendrick, B.Sc Veselin Kalfov, M.D Rienk Pypstra, M.D James M Rusnak
New England Journal of Medicine, doi:10.1056/nejmoa2309002
Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis.
METHODS We conducted a phase 2-3 double-blind trial to assess the efficacy and safety of nirmatrelvir-ritonavir in asymptomatic, rapid antigen test-negative adults who had been exposed to a household contact with Covid-19 within 96 hours before randomization. The participants were randomly assigned in a 1:1:1 ratio to receive nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir) every 12 hours for 5 days or for 10 days or matching placebo for 5 or 10 days. The primary end point was the development of symptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, confirmed on reverse-transcriptasepolymerase-chain-reaction (RT-PCR) or rapid antigen testing, through 14 days in participants who had a negative RT-PCR test at baseline.
RESULTS A total of 2736 participants were randomly assigned to a trial group -921 to the 5-day nirmatrelvir-ritonavir group, 917 to the 10-day nirmatrelvir-ritonavir group, and 898 to the placebo group. Symptomatic, confirmed SARS-CoV-2 infection developed by day 14 in 2.6% of the participants in the 5-day nirmatrelvir-ritonavir group, 2.4% of those in the 10-day nirmatrelvir-ritonavir group, and 3.9% of those in the placebo group. In each nirmatrelvir-ritonavir group, the percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly from that in the placebo group, with risk reductions relative to placebo of 29.8% (95% confidence interval [CI], -16.7 to 57.8; P = 0.17) in the 5-day nirmatrelvir-ritonavir group and 35.5% (95% CI, -11.5 to 62.7; P = 0.12) in the 10-day nirmatrelvir-ritonavir group. The incidence of adverse events was similar across the trial groups, with dysgeusia being the most frequently reported adverse event (in 5.9% and 6.8% of the participants in the 5-day and 10-day nirmatrelvir-ritonavir groups, respectively, and in 0.7% of those in the placebo group).
CONCLUSIONS In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection.
References
Dougherty, Mannell, Naqvi, Matson, Stone, SARS-CoV-2 B.1.617.2 (delta) variant COVID-19 outbreak associated with a gymnastics facility -Oklahoma, April-May 2021, MMWR Morb Mortal Wkly Rep
Liu, Liang, Zhong, Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing, Emerg Microbes Infect
Luo, Liu, Liao, Contact settings and risk for transmission in 3410 close contacts of patients with Covid-19 in Guangzhou, China: a prospective cohort study, Ann Intern Med
López-Muñoz, Torrella, Pérez-Quílez, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, Spain, Emerg Infect Dis
Madewell, Yang, Longini, Jr, Halloran et al., Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis, JAMA Netw Open
Park, Choe, Park, Contact tracing during coronavirus disease outbreak, South Korea, Emerg Infect Dis
{ 'indexed': {'date-parts': [[2024, 7, 18]], 'date-time': '2024-07-18T00:20:20Z', 'timestamp': 1721262020870},
'reference-count': 31,
'publisher': 'Massachusetts Medical Society',
'issue': '3',
'license': [ { 'start': { 'date-parts': [[2024, 7, 18]],
'date-time': '2024-07-18T00:00:00Z',
'timestamp': 1721260800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm'}],
'funder': [ { 'DOI': '10.13039/100004319',
'name': 'Pfizer Inc',
'doi-asserted-by': 'publisher',
'award': ['N/A']}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024, 7, 18]]},
'DOI': '10.1056/nejmoa2309002',
'type': 'journal-article',
'created': {'date-parts': [[2024, 7, 17]], 'date-time': '2024-07-17T21:01:07Z', 'timestamp': 1721250067000},
'page': '224-234',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19',
'prefix': '10.1056',
'volume': '391',
'author': [ { 'given': 'Jennifer',
'family': 'Hammond',
'sequence': 'first',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Carla',
'family': 'Yunis',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Robert J.',
'family': 'Fountaine',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Gerald',
'family': 'Luscan',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Aimee M.',
'family': 'Burr',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Wuyan',
'family': 'Zhang',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Wayne',
'family': 'Wisemandle',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-6140-9841',
'authenticated-orcid': False,
'given': 'Holly',
'family': 'Soares',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Mary Lynn',
'family': 'Baniecki',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Victoria M.',
'family': 'Hendrick',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Veselin',
'family': 'Kalfov',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'Rienk',
'family': 'Pypstra',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]},
{ 'given': 'James M.',
'family': 'Rusnak',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), '
'and Global Product Development, Pfizer, Tampa (J.M.R.) — both in '
'Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., '
'H.S.); Global Product Development, Pfizer International '
'Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical '
'and Safety...'}]}],
'member': '150',
'reference': [ {'key': 'e_1_3_5_2_2', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M20-2671'},
{'key': 'e_1_3_5_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3201/eid2610.201315'},
{ 'key': 'e_1_3_5_4_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/22221751.2020.1787799'},
{'key': 'e_1_3_5_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7028e2'},
{ 'key': 'e_1_3_5_6_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2022.9317'},
{ 'key': 'e_1_3_5_7_2',
'unstructured': 'UK Health Security Agency. SARS-CoV-2 variants of concern and variants '
'under investigation in England. Technical briefing 31. December 10 2021 '
'(https://assets.publishing.service.gov.uk/media/61c07740d3bf7f05570654e6/technical_briefing-31-10-december-2021.pdf).'},
{'key': 'e_1_3_5_8_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3201/eid2810.220494'},
{ 'key': 'e_1_3_5_9_2',
'unstructured': 'World Health Organization. Considerations for quarantine of contacts of '
'COVID-19 cases: interim guidance. June 25 2021 '
'(https://iris.who.int/bitstream/handle/10665/342004/WHO-2019-nCoV-IHR-Quarantine-2021.1-eng.pdf).'},
{ 'key': 'e_1_3_5_10_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S2214-109X(20)30074-7'},
{'key': 'e_1_3_5_11_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2110345'},
{'key': 'e_1_3_5_12_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-021-01446-y'},
{ 'key': 'e_1_3_5_13_2',
'unstructured': 'Centers for Disease Control and Prevention. Concerns about bivalent '
'COVID-19 vaccine and reasons for non-vaccination among adults who '
'completed a primary series — Omnibus survey March 10–April 30 2023 & '
'Household Pulse Survey March 1–April 10 2023 '
'(https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/pubs-resources/covid-vaccine-reasons-non-vaccination.html).'},
{'key': 'e_1_3_5_14_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3201/eid2901.221151'},
{ 'key': 'e_1_3_5_15_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S2214-109X(21)00593-3'},
{'key': 'e_1_3_5_16_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmi.2017.04.019'},
{'key': 'e_1_3_5_17_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciy874'},
{ 'key': 'e_1_3_5_18_2',
'unstructured': 'Merck provides update on phase 3 MOVe-AHEAD trial evaluating LAGEVRIO '
'(molnupiravir) for post-exposure prophylaxis for prevention of COVID-19. '
'February 21 2023 '
'(https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/).'},
{'key': 'e_1_3_5_19_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abl4784'},
{ 'key': 'e_1_3_5_20_2',
'unstructured': 'Fact sheet for healthcare providers: emergency use authorization for '
'Paxlovid (nirmatrelvir tablets; ritonavir tablets). New York: Pfizer '
'2024 (https://www.fda.gov/media/155050/download).'},
{ 'key': 'e_1_3_5_21_2',
'unstructured': 'Food and Drug Administration. FDA briefing document: drug name: '
'nirmatrelvir tablets and ritonavir tablets copackaged for oral use. '
'Antimicrobial Drugs Advisory Committee Meeting March 16 2023 '
'(https://www.fda.gov/media/166197/download).'},
{'key': 'e_1_3_5_22_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2309003'},
{ 'key': 'e_1_3_5_23_2',
'unstructured': 'Pfizer. Paxlovid: highlights of prescribing information. 2023 '
'(https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf).'},
{'key': 'e_1_3_5_24_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-021-88130-w'},
{ 'key': 'e_1_3_5_25_2',
'unstructured': 'Food and Drug Administration. Assessing COVID-19-related symptoms in '
'outpatient adult and adolescent subjects in clinical trials of drugs and '
'biological products for COVID-19 prevention or treatment: guidance for '
'industry. September 2020 '
'(https://digirepo.nlm.nih.gov/master/borndig/9918232103906676/9918232103906676.pdf).'},
{ 'key': 'e_1_3_5_26_2',
'doi-asserted-by': 'crossref',
'unstructured': 'Benjamini Y Hochberg Y. Controlling the false discovery rate: a '
'practical and powerful approach to multiple testing. J R Stat Soc Ser B '
'1995;57:289-300 '
'(https://www.stat.purdue.edu/~doerge/BIOINFORM.D/FALL06/Benjamini%20and%20Y%20FDR.pdf).',
'DOI': '10.1111/j.2517-6161.1995.tb02031.x'},
{ 'key': 'e_1_3_5_27_2',
'unstructured': 'National Institutes of Health. Coronavirus disease 2019 (COVID-19) '
'treatment guidelines. 2024 '
'(https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf).'},
{ 'key': 'e_1_3_5_28_2',
'unstructured': 'Food and Drug Administration. FDA announces bebtelovimab is not '
'currently authorized in any US region. November 30 2022 '
'(https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region).'},
{ 'key': 'e_1_3_5_29_2',
'unstructured': 'Food and Drug Administration. FDA announces Evusheld is not currently '
'authorized for emergency use in the U.S. January 26 2023 '
'(https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us).'},
{'key': 'e_1_3_5_30_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2022.9745'},
{ 'key': 'e_1_3_5_31_2',
'unstructured': 'ClinicalTrials.gov. A study to learn about the study medicines '
'(nirmatrelvir plus ritonavir) in people aged 12 years or older with '
'COVID-19 and a compromised immune system. 2024 '
'(https://clinicaltrials.gov/ct2/show/NCT05438602).'},
{ 'key': 'e_1_3_5_32_2',
'unstructured': 'ClinicalTrials.gov. A study to learn about the medicine called '
'nirmatrelvir used in combination with ritonavir in people with weakened '
'immune systems or at increased risk for poor outcomes who are '
'hospitalized due to severe COVID-19 (EPIC-HOS). 2023 '
'(https://www.clinicaltrials.gov/ct2/show/NCT05545319).'}],
'container-title': 'New England Journal of Medicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2309002',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 7, 17]],
'date-time': '2024-07-17T21:01:31Z',
'timestamp': 1721250091000},
'score': 1,
'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMoa2309002'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 7, 18]]},
'references-count': 31,
'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2024, 7, 18]]}},
'alternative-id': ['10.1056/NEJMoa2309002'],
'URL': 'http://dx.doi.org/10.1056/NEJMoa2309002',
'relation': {},
'ISSN': ['0028-4793', '1533-4406'],
'subject': [],
'container-title-short': 'N Engl J Med',
'published': {'date-parts': [[2024, 7, 18]]}}
